These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 5783335)

  • 1. [Case of primary myelofibrosis].
    Matsuda M; Sasaki T; Nishiie K; Sampi K; Takazawa T
    Naika; 1969 Feb; 23(2):383-7. PubMed ID: 5783335
    [No Abstract]   [Full Text] [Related]  

  • 2. [The activity of the alkaline phosphatase of neutrophils in myeloproliferative diseases].
    Vakulenko AD; Shubich MG
    Ter Arkh; 1966 Feb; 38(2):66-9. PubMed ID: 5235224
    [No Abstract]   [Full Text] [Related]  

  • 3. An unusual case of myeloproliferative disease which started with erythroderma: chronic (incomplete) panmyelosis.
    Gorini M; Ghizzi A; Bobbio Pallavicini E; Perugini S
    Haematologica; 1979 Dec; 64(6):804-11. PubMed ID: 161880
    [No Abstract]   [Full Text] [Related]  

  • 4. [Metamorphosis of chronic myeloproliferative diseases].
    Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
    [No Abstract]   [Full Text] [Related]  

  • 5. Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?
    Barosi G; Magrini U; Gale RP
    Leuk Res; 2010 Sep; 34(9):1119-20. PubMed ID: 20538336
    [No Abstract]   [Full Text] [Related]  

  • 6. Myeloproliferative disorder and tuberculosis.
    Herman I
    Calif Med; 1966 Oct; 105(4):287-90. PubMed ID: 5976885
    [No Abstract]   [Full Text] [Related]  

  • 7. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
    Gilbert HS
    Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis.
    Chen F; Zhang C; Wang W; Li L; Yan S; Sun J; Zhang M; Ji C; Hou M
    Leuk Res; 2008 Apr; 32(4):665-7. PubMed ID: 17854891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of myeloproliferative diseases].
    Burkhardt R
    Munch Med Wochenschr; 1973 May; 115(19):878-91. PubMed ID: 4800219
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary thrombocythemia. Clinical, hematological and chromosomal studies of 13 patients.
    Frick PG
    Helv Med Acta; 1969 May; 35(1):20-9. PubMed ID: 5814492
    [No Abstract]   [Full Text] [Related]  

  • 11. [Study of erythrocyte survival in relation to the predominant sites of their destruction in patients with osteomyelosclerosis and myelofibrosis].
    Sakhibov IaD; Aripov AIa
    Ter Arkh; 1968 Apr; 40(4):92-7. PubMed ID: 5740515
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pathogenesis of marrow fibrosis in myeloproliferative disorders].
    Wróbel T; Podolak-Dawidziak M
    Pol Arch Med Wewn; 1998 Jan; 99(1):70-7. PubMed ID: 9686507
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversible myelofibrosis?
    Lancet; 1985 Mar; 1(8427):497-9. PubMed ID: 2857858
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.
    Andrieux J; Roche-Lestienne C; Geffroy S; Desterke C; Grardel N; Plantier I; Selleslag D; Demory JL; Laï JL; Leleu X; Le Bousse-Kerdiles C; Vandenberghe P
    Cancer Genet Cytogenet; 2007 Oct; 178(1):11-6. PubMed ID: 17889703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelofibrosis in the myeloproliferative disorders.
    Ellis JT; Peterson P
    Prog Clin Biol Res; 1984; 154():19-42. PubMed ID: 6382293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paroxysmal nocturnal hemoglobinuria. I. Concept and pathogenesis of the disease].
    Solovera Cano JJ; Frieyro Seguí JE; Ferriz P; Pérez Maestu R; Fraile de Abajo L; Elviro P; Masa Vázquez C
    Rev Clin Esp; 1981 Jan; 160(1):1-7. PubMed ID: 7010470
    [No Abstract]   [Full Text] [Related]  

  • 18. [The treatment of patients with erythema with the use of radioactive phosphorus (clinical observations)].
    Kozyreva AL
    Sov Med; 1967 Dec; 30(12):64-7. PubMed ID: 5606296
    [No Abstract]   [Full Text] [Related]  

  • 19. The spleen as a source of colony-forming cells in myelofibrosis.
    Adamson JW; Powell JS
    Prog Clin Biol Res; 1984; 154():323-34. PubMed ID: 6382301
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypocholesterolemia in myeloproliferative diseases with myelofibrosis.
    Ginsberg H; Gilbert HS
    Prog Clin Biol Res; 1984; 154():345-57. PubMed ID: 6382303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.